ClinicalTrials.gg
TerminatedNCT01118728SUSTAINUpdated Jun 21, 2017Results posted

Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis

A Phase 2 interventional study of Sarilumab in Ankylosing Spondylitis, sponsored by Sanofi. Terminated at 12 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-21.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Why this study was terminated
Lack of benefit on efficacy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
223
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 87 studies in Spondylitis, Ankylosing with a site in United States — 10 open to participants now, 13 under way, none of them phase 3. Spondylitis, Ankylosing · United States.

Enrollment
30th of 59
223 · median 223
Started
2010
with 4 others
Phase 2
18 of 87
1 open now
Registered
17th of 87
by date

Among the 87 studies in Spondylitis, Ankylosing with a site in United States, this one is the 30th largest by enrollment of the 59 interventional ones that give a count, is one of 5 that started in 2010, is one of 18 in phase 2, and was the 17th registered.

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

10 of the 87 studies in Spondylitis, Ankylosing with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Spondylitis, Ankylosing with a site in United States, or all of them as a file.
02

Study summary

Primary Objective:

  • To assess the long term safety of Sarilumab (SAR153191/REGN88) in participants with ankylosing spondylitis (AS)

Secondary Objective:

  • To assess the long term efficacy of Sarilumab (SAR153191/REGN88) in participants with AS
Read the detailed description

The maximum study duration per participant was to be 267 weeks (approximately 5 years) broken down as follows:

  • screening up to a maximum of 1 week;
  • treatment up to a maximum of 260 weeks;
  • follow-up of 6 weeks after treatment discontinuation.
03

Conditions studied

  • Ankylosing Spondylitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant with AS who participated and completed 12-week treatment in study DRI11073-NCT01061723.

Exclusion criteria

Exclusion criteria:

  • Adverse event(s) having lead to treatment discontinuation in the DRI11073 study;
  • Event or laboratory abnormality observed at the last treatment visit of DRI11073 study that would have adversely affected participation of the participant in this study as per investigator judgment.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
223 participants (actual)

Study arms

  • Experimental
    Sarilumab

    Sarilumab 150 mg subcutaneous (SC) injection every week (or every other week in case of safety issue) for 260 weeks, or until commercially available, or until discontinuation of the project, whichever came first.

    Drug: Sarilumab

Interventions

  • Pharmaceutical form: solution for injection Route of administration: subcutaneous

    Also known as: SAR153191, REGN88

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Any Treatment-emergent Adverse Event (TEAE), Serious Adverse Event (SAE) and Treatment Discontinuation

    An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, regardless of the relationship to the investigational medicinal product (IMP). SAE was any untoward medical occurrence that at any dose resulted in death or was life-threatening or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect or was a medically important event. TEAEs were AEs that developed or worsened or became serious during the TEAE period (time from first dose of IMP up to the end of follow-up period).

    Time frame: Baseline up to the end of study (66 weeks)

Secondary outcomes

  1. Percentage of Participants Who Achieved 20% Response in Ankylosing Spondylitis (AS) Working Group Criteria for Response (ASAS20)

    Treatment response for ASAS20 was defined as: Improvement of ≥ 20% and ≥ 1 unit on a 0 (least) to 10 (worst) numerical rating score (NRS) in at least 3 of the 4 ASAS improvement criteria (ASASIC) domains, and no worsening of ≥ 20% and ≥ 1 unit on 0-10 NRS in the remaining domain. The 4 domains included were participant's global disease activity assessment, total back pain, physical function (Bath Ankylosing Spondylitis Functional Index), and Inflammation (mean of last 2 Bath Ankylosing Spondylitis Disease Activity Index questions on morning stiffness).

    Time frame: Baseline up to the end of treatment (60 weeks)

07

Results

Posted Jun 21, 2017
Limitations and caveats
The study was prematurely discontinued after approximately 1.5 years, when the ankylosing spondylitis development program was discontinued due to lack of efficacy in the DRI11073 study.

Participant flow

The study was conducted at 56 centers in 12 countries. A total of 224 participants were screened between 01 June 2010 and 03 June 2011.

Participant flow — Overall Study
MilestoneSarilumab
Started223
Completed0
Not completed223
Withdrew: Adverse event17
Withdrew: Lack of efficacy27
Withdrew: Sponsor's decision to discontinue study172
Withdrew: Withdrawal by subject3
Withdrew: Lost to follow-up4

Outcome measures

PrimaryPercentage of Participants Experiencing Any Treatment-emergent Adverse Event (TEAE), Serious Adverse Event (SAE) and Treatment Discontinuation

An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, regardless of the relationship to the investigational medicinal product (IMP). SAE was any untoward medical occurrence that at any dose resulted in death or was life-threatening or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect or was a medically important event. TEAEs were AEs that developed or worsened or became serious during the TEAE period (time from first dose of IMP up to the end of follow-up period).

Time frame:
Baseline up to the end of study (66 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing Any Treatment-emergent Adverse Event (TEAE), Serious Adverse Event (SAE) and Treatment Discontinuation
Percentage of participantsSarilumab
Any TEAE67.3
Any treatment-emergent SAE5.4
Any TEAE leading to treatment discontinuation8.1
SecondaryPercentage of Participants Who Achieved 20% Response in Ankylosing Spondylitis (AS) Working Group Criteria for Response (ASAS20)

Treatment response for ASAS20 was defined as: Improvement of ≥ 20% and ≥ 1 unit on a 0 (least) to 10 (worst) numerical rating score (NRS) in at least 3 of the 4 ASAS improvement criteria (ASASIC) domains, and no worsening of ≥ 20% and ≥ 1 unit on 0-10 NRS in the remaining domain. The 4 domains included were participant's global disease activity assessment, total back pain, physical function (Bath Ankylosing Spondylitis Functional Index), and Inflammation (mean of last 2 Bath Ankylosing Spondylitis Disease Activity Index questions on morning stiffness).

Time frame:
Baseline up to the end of treatment (60 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved 20% Response in Ankylosing Spondylitis (AS) Working Group Criteria for Response (ASAS20)
Percentage of participantsSarilumab
Week 0 (n=218)30.3
Week 12 (n=207)40.1
Week 24 (n=150)46.0
Week 36 (n=93)41.9
Week 48 (n=37)59.5
Week 60 (n=7)57.1

Adverse events

Collected over All AEs were collected from signature of the informed consent form up to the final visit (Day 414) regardless of seriousness or relationship to investigational product. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sarilumab—12/223 (5.4%)62/223 (27.8%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventSarilumab
NephrolithiasisRenal and urinary disorders2/223
CellulitisInfections and infestations1/223
DiverticulitisInfections and infestations1/223
GastroenteritisInfections and infestations1/223
LaryngitisInfections and infestations1/223
Thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/223
Thyroid neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/223
Crohn's diseaseGastrointestinal disorders1/223
Skin necrosisSkin and subcutaneous tissue disorders1/223
Ankylosing spondylitisMusculoskeletal and connective tissue disorders1/223
Most frequent other events
Most frequent other events
EventSarilumab
NeutropeniaBlood and lymphatic system disorders21/223
NasopharyngitisInfections and infestations16/223
Injection site reactionGeneral disorders14/223
Upper respiratory tract infectionInfections and infestations13/223
Aphthous stomatitisGastrointestinal disorders12/223

Baseline characteristics

All enrolled participants who received at least one dose of the study treatment after signature of the informed consent.

Age, Continuous
Age, Continuous(Years)Sarilumab
Mean41.6 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)Sarilumab
Female63
Male160
08

Study locations

12 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis Administrative Office
    Macquarie Park, New South Wales, Australia
  • Sanofi-Aventis Administrative Office
    Wien, Austria
  • Sanofi-Aventis Administrative Office
    Diegem, Belgium
  • Sanofi-Aventis Administrative Office
    Laval, Canada
  • Sanofi-Aventis Administrative Office
    Praha, Czechia
  • Sanofi-Aventis Administrative Office
    Paris, France
  • Sanofi-Aventis Administrative Office
    Budapest, Hungary
  • Sanofi-Aventis Administrative Office
    Vilnius, Lithuania
  • Sanofi-Aventis Administrative Office
    Gouda, Netherlands
  • Sanofi-Aventis Administrative Office
    Warszawa, Poland
  • Sanofi-Aventis Administrative Office
    Barcelona, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2017, 5 years 6 months after primary completion. A results delay was requested in Jan 2013.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2010
First posted
May 7, 2010
Start
Jun 2010
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Results delay requested
Jan 11, 2013
Results first posted
Jun 21, 2017
Last update
Jun 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01118728
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 7, 2010
Start date
Jun 2010
Primary completion
Dec 2011
Completion
Dec 2011
Results posted
Jun 21, 2017
Last update
Jun 21, 2017

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sarilumab

Start the discussion